Company intelligence / Profile preview
Sojournix
Waltham, Massachusetts, United Statessojournixpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sojournix’s lead drug candidate, SJX‑653, a potent and selective neurokinin‑3 receptor antagonist, has demonstrated clinical proof-of-mechanism in treating moderate to severe vasomotor symptoms associated with menopause. A Phase 2 randomized, double-blind placebo-controlled trial was conducted but terminated; however, data showed efficacy and safety consistent with the mechanism of action[3]. The company focuses on innovative medicines addressing unmet needs in women’s health and endocrine disorders.
- Therapeutic areas
- Women's Health
- Modalities
- Small molecules (notably neurokinin receptor antagonists)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Sojournix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sojournix.